US Drug Prices "Twice As High" As Elsewhere

7 August 1994

Three disturbing facts are becoming increasingly clear regarding US drugs and their prices, said Peter Arno, associate professor at the Montefiore Medical Center/Albert Einstein College of Medicine, New York, delivering testimony before the US Senate Committee on Government Affairs at the end of July.

These are, he pointed out: - the average price of drugs in the USA is far higher than the same drugs in other industrialized countries; - the rate of drug price inflation in the USA continues to exceed inflation in the general economy; and - half of all expenditures on prescription drugs are still paid for out-of-pocket.

As things stand currently, Prof Arno said, "pharmaceutical practices and gaps in insurance coverage for needed therapies are a grave disservice to the citizens of this country in their capacities as both health consumers and taxpayers."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight